Indicated for the treatment of Swine Respiratory Disease (SRD)
Tulissin 25® injectable solution is indicated for the treatment of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis, and Mycoplasma hyopneumoniae. Do not inject more than 4 mL per injection site. Swine intended for human consumption must not be slaughtered within 5 days from the last treatment.
Tulissin 25® injectable solution is indicated for the the control of SRD associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, and Mycoplasma hyopneumoniae in groups of pigs where SRD has been diagnosed. Not for use in animals previously found to be hypersensitive to the drug.
Two concentrations for added flexibility based on weight
Tulissin® 25 injectable solution is formulated for weaned pigs for increased precision
Tulissin 25 mg/mL For swine: 1 mL/22 lb. BW
Tulissin® 100 (tulathromycin injection) is available for use in larger pigs. Note effects on swine reproduction and lactation have not been determined.
Waag TA, Bradford JR, Lucas MJ, et al. Duration of effectiveness of tulathromycin injectable solution in an Actinobacillus pleuropneumoniae respiratory-disease challenge model in swine. J Swine Health Prod. 2008;16(3):126–130.
Villarino N, Brown SA, Martín-Jiménez T. Understanding the pharmacokinetics of tulathromycin: a pulmonary perspective. J. Vet Pharmacol. Therap. 37, 211- 221.
Benchaoui HA, Nowakowski M, Sherington J, Rowan TG, Sunderland SJ. Pharmacokinetics and lung tissue concentrations of tulathromycin in swine. J. Vet Pharmacolo. Therap. 2004;27(4):203-210.)